Regeneron (REGN) – Globe Newswire
-
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
-
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
-
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Seriou
-
Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
-
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
-
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
-
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
-
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
-
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
-
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
-
Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
-
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
-
EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
-
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
-
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
-
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023
-
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
-
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
-
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
-
Regeneron Provides Update on Planned Chief Financial Officer Transition
-
Regeneron Announces Updates to Board of Directors
-
Regeneron Announces Investor Conference Presentations
-
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention
-
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
-
Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease
-
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
-
Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration
-
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs
-
Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation
-
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
-
Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023
-
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema
-
FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler
-
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
-
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
-
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
-
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
-
High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
-
Regeneron Announces Investor Conference Presentations
-
Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation
-
Regeneron Reports First Quarter 2023 Financial and Operating Results
-
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
-
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research
-
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
-
Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary
-
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
-
Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases
-
Regeneron Announces Investor Conference Presentations
Back to REGN Stock Lookup
